Montaser Shaheen

Suggest Changes
Learn More
OBJECTIVE This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior(More)